Advertisement

Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in General Population: the French Nationwide NASH-CO Study

      The burden of nonalcoholic fatty liver disease (NAFLD) and advanced fibrosis has not been reported so far at a nationwide level in Europe. According to a meta-analysis, the prevalence of NAFLD in European countries ranged from 4% to 50%, reflecting the heterogeneity of study populations.
      • Younossi Z.M.
      • et al.
      The French CONSTANCES population-based cohort was designed as a large representative sample for age, gender, and socioeconomic status of the French adult population.
      • Zins M.
      • et al.
      The present study was aimed to assess the prevalence of NAFLD and advanced fibrosis in the CONSTANCES cohort by using noninvasive markers, and to examine risk factors associated with these conditions.

      Keywords

      Abbreviations used in this paper:

      ALT (alanine aminotransferase), CI (confidence interval), FI (Forns Index), FLI (Fatty Liver Index), HSC (Health Screening Center), NAFLD (nonalcoholic fatty liver disease), OR (odds ratio)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Younossi Z.M.
        • et al.
        Hepatololgy. 2016; 64: 73-84
        • Zins M.
        • et al.
        Eur J Epidemiol. 2015; 30: 1317-1328
        • Bedogni G.
        • et al.
        BMC Gastroenterol. 2006; 6: 33
        • Matta J.
        • et al.
        Presse Med. 2018; 47: 434-438
        • Koehler E.M.
        • et al.
        Clin Gastroenterol Hepatol. 2013; 11: 1201-1204
        • Younossi Z.M.
        • et al.
        Gut. 2020; 69: 564-568
        • Golabi P.
        • et al.
        Liver Int. 2019; 39: 748-757
        • Koehler E.M.
        • et al.
        Hepatology. 2016; 63: 138-147

      Supplementary References

        • Zins M.
        • et al.
        Eur J Epidemiol. 2015; 30: 1317-1328
        • Boursier J.
        • et al.
        J Hepatol. 2017; 66: 1158-1165
        • Kleiner D.E.
        • et al.
        Hepatology. 2005; 41: 1313-1321
        • Forns X.
        • et al.
        Hepatology. 2002; 36: 986-992
        • Sterling R.K.
        • et al.
        Hepatology. 2006; 43: 1317-1325
        • Wai C.T.
        • et al.
        Hepatology. 2003; 38: 518-526